10-K: Aspira Women's Health Amends Warrants, Pursues Strategic Alternatives Amidst Financial Uncertainty

Aspira Women's Health is amending warrants and seeking additional capital to address financial challenges and continue operations.

Summary

• Aspira Women's Health is focused on developing AI-powered diagnostic tests for gynecologic diseases, particularly ovarian cancer and endometriosis.
• The company is expanding its commercial focus to include a broader range of gynecological conditions and distributing tests through its Aspira Synergy platform.
• Aspira's current capital resources are insufficient to fund operations for the remainder of 2025, prompting the pursuit of strategic alternatives and additional capital.
• On March 5, 2025, Aspira entered into a securities purchase agreement for $1,365,000 in Senior Secured Convertible Promissory Notes with existing accredited shareholders.
• The Convertible Notes are convertible into units of common stock and warrants, with interest accruing at 3.34% and maturing on March 6, 2030.
• The company has the option to convert the Convertible Notes into units if net proceeds from the sale of the Convertible Notes and subsequent sales of common stock and warrants equals or exceeds $4 million.
• The holders of the Notes are entitled to three representatives on the board of directors.
• The company's OvaWatch test has seen a tenfold increase in its addressable market, now estimated at 2 to 4 million tests per year.
• Aspira is developing OVAinform, a multi-marker test for ovarian cancer risk assessment, and ENDOinform, a non-invasive test for endometriosis diagnosis.
• The company is collaborating with academic institutions to develop and validate biomarkers for diagnostic assays.
• Aspira Labs, the company's CLIA-certified lab, performs Ova1Plus and OvaWatch testing and plans to expand to other gynecologic conditions.
• The company faces competition in the diagnostics industry and is working to expand payer coverage and reimbursement for its products.
• Aspira is subject to FDA regulations for its diagnostic tests and must comply with CLIA requirements for its clinical laboratory operations.
• The company's ability to utilize net operating loss carryforwards may be limited due to ownership change limitations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in product development and market expansion, the company's financial challenges and going concern uncertainty weigh heavily on the overall sentiment.

Positives

• The addressable market for Aspira's tests has increased significantly due to the expansion of the OvaWatch test.
• The company is developing new diagnostic tests for ovarian cancer and endometriosis, addressing large unmet needs.
• Aspira Labs holds a CLIA Certificate of Accreditation and a state laboratory license in multiple states, enabling national testing services.
• The company has secured reimbursement for OvaWatch and Ova1 tests processed for Medicare patients at a rate of $897.
• The company has a comprehensive reimbursement plan for Ova1 and OvaWatch, and has targeted third-party payers, Medicare, Medicare Advantage, State Medicaid and Managed Medicaid plans for coverage and reimbursement.

Negatives

• Aspira's current capital resources are insufficient to fund operations for the remainder of 2025.
• The company has incurred significant losses and negative cash flows from operations since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may need to sell additional shares of common stock or other securities in the future to meet capital requirements, which could cause significant dilution.
• The company faces competition in the diagnostics industry.
• The company's ability to utilize net operating loss carryforwards may be limited due to ownership change limitations.
• The company's internal control over financial reporting was not effective as of December 31, 2024.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may need to raise additional capital, which may not be available on acceptable terms.
• Failures by third-party payers to reimburse for the company's products and services could materially and adversely affect the business.
• The company may not succeed in improving existing or developing additional diagnostic products.
• The diagnostics market is competitive, and the company may not be able to compete successfully.
• The company is subject to environmental laws and potential exposure to environmental liabilities.
• The company's ability to utilize its net operating loss carryforwards may be limited.
• The company's stock price has been, and may continue to be, highly volatile.
• The company's internal control over financial reporting was not effective as of December 31, 2024.

Future Outlook

Aspira expects to continue commercializing existing and new technology, distributing tests through Aspira Synergy, and raising public awareness regarding the diagnostic superiority of the Ova1Plus workflow. The company also plans to expand access to its tests among Medicaid patients and advocate for legislation and the adoption of its technology in professional society guidelines.

Management Comments

• Management believes the successful achievement of our business objectives will require additional financing.
• Management concluded our internal control over financial reporting as of December 31, 2024 was not effective.

Industry Context

The global in vitro diagnostic (IVD) market is forecasted to reach $117.6 billion by 2032, growing at a compound annual growth rate of 6.0% from 2024 to 2032. Aspira is concentrating its business focus in the areas of gynecologic oncology and disease where it has established strong key opinion leaders, and provider and patient relationships.

Comparison to Industry Standards

• Fujirebio Diagnostics sells ROMA, a test with the same intended use and precautions as Ova1.
• Competitors such as AOA Dx, ClearNote Health, Cleo Diagnostics and Mercy BioAnalytics, and others have publicly disclosed that they have been or are currently working on ovarian cancer diagnostic assays.
• Exact Sciences, Grail and others are working on multi-cancer early diagnostic tests that include ovarian cancer detection.
• Competitors for our endometriosis offerings include, but are not limited to, Afynia, DotLab, Endodiag, HERA Biotech Heranova, Proteomics International. and Ziwig.

Management Changes

Related Party Transactions

• On December 1, 2023, the Company entered into a consulting agreement with Biodesix, Inc. (the Biodesix Agreement) to assist with our miRNA product pipeline. Jack Schuler, a beneficial owner of more than 10 % of the Companys stock, is also a beneficial owner of more than 10 % of the stock of Biodesix, Inc.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through the sale of equity or convertible debt.
• Employees may be affected by cost-cutting measures or changes in operations.
• Customers may benefit from the development of new diagnostic tests.
• Suppliers and creditors may be affected by the company's financial challenges.

Next Steps

• The company will continue to pursue strategic alternatives and seek additional capital.
• The company will continue to commercialize existing and new technology and distribute tests through the Aspira Synergy platform.
• The company will continue to develop OVAinform and ENDOinform, multi-marker tests for ovarian cancer and endometriosis, respectively.
• The company will continue to expand access to its tests among Medicaid patients and advocate for legislation and the adoption of its technology in professional society guidelines.

Key Dates

Keywords

Ovarian Cancer, Endometriosis, Diagnostic Tests, Aspira Women's Health, Capital Raise, Warrants, Financial Condition, Reimbursement, FDA Regulation, CLIA, OvaWatch, OVAinform, ENDOinform, Aspira Labs, Going Concern